# EDGAR Filing Document

**Accession Number:** 0001984086
**File Stem:** 0001193125-25-142747
**Filing Date:** 2025-6
**Character Count:** 6861
**Document Hash:** c4297693e89cc906d680f591cf246be8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-142747.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001193125-25-142747

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Septerna, Inc.
- **CENTRAL INDEX KEY:** 0001984086
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843891440
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42382
- **FILM NUMBER:** 251057375

**BUSINESS ADDRESS:**
- **STREET 1:** 250 EAST GRAND AVENUE, SUITE 65
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-338-3533

**MAIL ADDRESS:**
- **STREET 1:** 250 EAST GRAND AVENUE, SUITE 65
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 17, 2025

## Septerna, Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42382** | **84-3891440** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **250 East Grand Avenue** |  |
| **South San Francisco, California** | **94080** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

(650) 338-3533

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value per share | SEPN | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 17, 2025, Septerna, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting") in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company's definitive proxy statement (the "Proxy Statement") filed on April 29, 2025 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 21, 2025, the record date for the Annual Meeting, the number of shares of the Company's common stock, $0.001 par value per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting was 44,515,703. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 34,278,489, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Annual Meeting.

At the Annual Meeting, the Company's stockholders were asked to vote on the following matters, which were described in detail in the Proxy Statement: (i) to elect two Class I director nominees to the Company's Board of Directors (the "Board"), each to serve for a three-year term until the Company's 2028 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal ("Proposal No. 1") and (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 ("Proposal No. 2").

The voting results reported below are final.

<u>Proposal No. 1</u> 

Abraham Bassan, M.S. and Alan Ezekowitz, M.D., D.Phil. were duly elected to the Board as Class I directors. The results of the stockholders' vote with respect to the election of the Class I directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **CLASS I DIRECTOR NOMINEE** | **FOR** | **WITHHELD** | **BROKER<br>NON-<br>VOTES** |
|  Abraham Bassan, M.S. | 29320969 | 3286107 | 1671413 |
|  Alan Ezekowitz, M.D., D.Phil. | 29195219 | 3411857 | 1671413 |

---

<u>Proposal No. 2</u> 

The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. The results of the stockholders' vote with respect to such ratification were as follows:

---

| | | |
|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** |
|  34,218,829 | 12,108 | 47,552 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SEPTERNA, INC.** | **SEPTERNA, INC.** |
| Date: June 18, 2025 | By: | /s/ Jeffrey Finer, M.D., Ph.D. |
|  | Name: | Jeffrey Finer, M.D., Ph.D. |
|  | Title: | President and Chief Executive Officer |

---